Back to Journals » Journal of Asthma and Allergy » Volume 3
Controversial data on simvastatin in asthma: What about the rat model?
Authors Tschernig , Bäumer W, Pabst R
Published 16 July 2010 Volume 2010:3 Pages 57—63
Review by Single anonymous peer review
Peer reviewer comments 3
Thomas Tschernig1, Wolfgang Bäumer2, Reinhard Pabst1
1Institute of Functional and Applied Anatomy, Hannover Medical School, Hannover, 2Institute of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Hannover, Germany
Abstract: The effects of simvastatin on lung inflammation in asthma are controversial. Reduction of inflammation and hyperreactivity has been reported in studies using murine models of asthma. In contrast, a clinical study has not found beneficial effects in patients. The rat model of asthma has some distinct advantages and is still widely used in industrial studies. Therefore, the role of simvastatin was investigated in this rat model using intraperitoneal and intratracheal administration. With both simvastatin administration routes, the relative and absolute numbers of neutrophils, eosinophils, and lymphocytes were only partially reduced after increasing dosages (0.1, 1.0, and 10 mg per animal). The most obvious effect was on CD4 T cell numbers, which were reduced in most treatment groups. The results presented here suggest that treatment with simvastatin differs between species, and that it is too early for extrapolation of these data to humans.
Keywords: simvastatin, inflammation, rat, asthma
© 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.